Financial Information for the 2nd Quarter of Fiscal Year Ending March 31, 2021

As of November 4, 2020

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma

(Note about forward-looking information)
The statements contained in this presentation is based on a number of assumptions and belief in light of the information currently available to management of the company and is subject to significant risks and uncertainties. It contains information about pharmaceuticals including products under development, but is not intended for advertising or medical advice.

Table of Contents

1 Summary of Financial Results for the 2nd Quarter of FY2020 Ending March 31, 2021 and Forecasts for FY2020

<Regarding GILENYA Royalty>

As Mitsubishi Tanabe Pharma Corporation (hereinafter, "MTPC") announced on April 24, 2019 in the "Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019", MTPC is currently in the arbitration proceedings with Novartis Pharma AG (hereinafter "Novartis"), and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts, which correspond to the clauses in the 1997 License Agreement of which Novartis has protested the validity, as our revenue because such payments do not satisfy one of the requirements under IFRS15, i.e., "Revenue under contract with customers". During the period of the arbitration proceedings, MTPC will continue the same accounting practice as MTPC did in fiscal year 2018. For fiscal year 2020, the forecast is prepared on the assumption that the arbitration procedure to continue.
MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration. As for the amounts among the GILENYA Royalty amounts which will not be recognized as sales revenue, those will be recognized as revenue at the end of the arbitration, depending on the outcome of the arbitration.

1. Summary of Financial Results for the 2nd Quarter of FY2020

(Amounts less than ¥100 million are rounded)

[Billion yen]

Revenue	187.3	Y-on-Y	(0.8)	(0.4 %)
Domestic	155.0	Y-on-Y	0.4	0.3 %
Overseas	32.3	Y-on-Y	(1.2)	(3.6 %)

Domestic ethical drugs sales increased by 0.8% to ¥150.3 billion, due to increase of SIMPONI for Rheumatoid arthritis (RA) etc. treatment, CANAGLU and CANALIA for type 2 diabetes mellitus treatment and RUPAFIN for allergy treatment, in addition to contribution of STELARA additionally approved for ulcerative colitis treatment in March 2020 and early shipment of influenza vaccine, despite NHI price revision in April 2020.
Royalty revenue, etc. decreased by 15.1% to ¥7.8 billion due to the decline in royalty revenue from GILENYA for multiple sclerosis treatment licensed to Novartis etc.

[Billion yen]

Core Operating Profit*1	14.6	Y-on-Y	2.9	24.5 %

Core operating profit increased due to SG&A and R&D expenses contained by voluntary restraint in activities under COVID-19 spread, despite a slight decrease in sales revenue.

[Billion yen]

Operating Profit*2	(61.9)	Y-on-Y	(74.5)	-

As for non-recurring items;
Profitability of NeuroDerm's projects for Parkinson's Disease is expected to decline due to delayed clinical study and the competitors' development status. As a result of reviewing the business plan based on the results of recent market research, we recorded an impairment loss of 84.5 billion Japanese yen for intangible assets related to above projects. Gain from fixed assets in transfer of Toda office, etc. booked ¥8.1 billion as well.

[Billion yen]

Profit before tax for the period*2	(61.6)	Y-on-Y	(73.7)	-
Net Income Attributable to owners of the Company*2	(51.0)	Y-on-Y	(59.3)	-

2. Summary of Forecasts for FY2020

[Billion yen]

Revenues	373.0	Y-on-Y	(6.8)	(1.8 %)
Core Operating Profit	17.0	Y-on-Y	(2.1)	(10.8 %)
Operating Profit *2	(62.5)	Y-on-Y	(56.4)	-
Profit before Tax*2	(62.0)	Y-on-Y	(55.5)	-
Net Income Attributable to owners of the Company*2	(52.5)	Y-on-Y	(52.6)	-

The Company modified full-year forecasts on Nov. 4, 2020. Refer to P5 "Forecasts for FY2020"

*1 With adoption of IFRS, the Company, its subsidiaries and its affiliates (collectively, "the Group") has introduced "core operating profit" as a major profit index to demonstrate its recurring profitability and positioned as an important indicator of business management, etc. "Core operating profit" is a profit excluding the income and loss recorded by non-recurring items specified by the Group (hereinafter "non-recurring items") from operating profit. The Company assumes gain or loss associated with a business transfer, restructuring loss, impairment losses on intangible assets associated with products and others as non-recurring items.

*2 Brackets indicate expense and loss

2 Consolidated Financial Indicators for the 2nd Quarter of FY2020

(Amounts less than ¥100 million are rounded)

1. Profit and Loss

(1) Profit and Loss

[Billion yen]

	Q2 FY2020	Comparison to previous year			Comparison to Forecasts		Notes [Y-on-Y comparison]
		Q2 FY2019	Increase (decrease)	Change %	Forecasts*1	Change %	
Revenue	**187.3**	188.1	(0.8)	(0.4)	373.0	50.2	Refer to "(2) Sales Revenue of Main Products"
Domestic	**155.0**	154.6	0.4	0.3	312.2	49.7	
Overseas	**32.3**	33.5	(1.2)	(3.6)	60.8	53.1	
Overseas sales ratio	**17.2%**	17.8%			16.3%		
Cost of sales	**94.8**	88.5	6.3	7.1	187.5	50.6	Deteriorated by NHI price revision, etc.
Sales cost ratio	**50.6%**	47.1%			50.3%		
Gross profit	**92.5**	99.6	(7.1)	(7.1)	185.5	49.9	
SG&A expenses, etc.	**77.9**	87.9	(10.0)	(11.4)	168.5	46.2	
R&D expenses	**33.9**	39.8	(5.9)	(14.8)	72.5	46.7	
Core operating profit*2	**14.6**	11.7	2.9	24.5	17.0	85.7	
Non-recurring items*3	**(76.5)**	0.9	(77.3)	-	(79.5)	-	Gain from sales of Toda Office:7.5 Impairment loss from NeuroDerm projects:84.5
Operating profit*3	**(61.9)**	12.6	(74.5)	-	(62.5)	-	
Financial income and loss*3	**0.3**	(0.4)	0.7	-			
Profit before tax for the period*3	**(61.6)**	12.1	(73.7)	-	(62.0)	-	
Income taxes	**(8.9)**	6.0	(14.9)	-			
Net profit for the period*3	**(52.7)**	6.2	(58.9)	-	(55.0)	-	
Net profit attributable to owners of the Company*3	**(51.0)**	8.3	(59.3)	-	(52.5)	-	

[Yen]

Exchange rate	Q2 FY2020 average	Q2 FY2019 average	FY2020 planned
USD	**106.32**	108.67	108.00

Effect of fluctuations in exchange rate for FY2020 Q2: Revenue decreased by ¥0.5 billion and core operating profit increased by ¥1.1 billion.

(2) Sales Revenue of Main Products

[Billion yen]

	Q2 FY2020	Comparison to previous year			Comparison to Forecasts	
		Q2 FY2019	Increase (decrease)	Change %	Forecasts*1	Change %
Domestic ethical drugs	**150.3**	149.2	1.2	0.8	302.3	49.7
Priority products	**89.9**	88.7	1.1	1.3	183.0	49.1
Remicade	**23.4**	27.6	(4.2)	(15.2)	45.0	52.0
Simponi	**21.2**	20.5	0.7	3.6	42.7	49.6
Stelara	**14.0**	12.6	1.4	10.9	31.9	43.7
Tenelia	**8.0**	8.1	(0.1)	(1.5)	14.9	53.5
Canaglu	**5.0**	4.1	0.9	22.8	9.8	51.4
Canalia	**5.0**	3.8	1.3	33.6	9.3	53.9
Vafseo (launched in Aug.)	**0.3**	-	0.3	-	0.5	60.6
Lexapro	**7.6**	7.5	0.2	2.1	14.8	51.4
Rupafin	**3.2**	2.5	0.7	29.0	10.0	32.2
Imusera	**2.1**	2.2	(0.0)	(2.1)	4.1	52.1
Vaccines	**21.1**	15.7	5.4	34.3	40.8	51.8
Influenza vaccine	**6.3**	1.8	4.5	253.2	13.2	47.9
Tetrabik	**5.1**	4.6	0.6	12.5	11.1	46.4
Mearubik	**3.7**	3.5	0.2	5.3	6.4	57.8
JEBIK V	**2.9**	2.9	0.0	1.3	5.3	55.1
Varicella vaccine	**2.5**	2.5	(0.0)	(0.6)	4.8	51.9
Long-listed drugs, etc.	**39.3**	44.7	(5.4)	(12.0)	78.5	50.1
Overseas ethical drugs	**25.1**	24.9	0.3	1.0	47.0	53.5
Radicava	**11.1**	11.6	(0.6)	(4.9)	20.1	55.1
Royalty revenue, etc.	**7.8**	9.2	(1.4)	(15.1)	15.2	51.5
Royalty from INVOKANA	**4.6**	4.1	0.5	11.8	Undisclosed	-
Royalty from GILENYA*4	**2.0**	3.3	(1.3)	(40.3)	Undisclosed	-

*1: The Company modified full-year forecasts on Nov. 4, 2020. Refer to P5 "Forecasts for FY2020"

*2: COVID-19 impact:¥5.5 billion. Decreased expenses by shrinkage in sales promotion and delay in R&D expenses incurrence overtake sales decrease by consultation restraint.

*3: Brackets indicate expense and loss

*4: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

2. Financial Statement

(1) Balance Sheet

[Billion yen]

	End of Q2 FY2020	End of FY2019	Increase (decrease)	Notes
Assets	**992.0**	1,046.3	(54.3)	
Non-current assets	**372.5**	452.8	(80.3)	
Property, plant and equipment	**89.8**	86.1	3.7	Obtain 9.4, depreciation(5.6), etc.
Goodwill	**89.6**	89.7	(0.1)	
Intangible assets	**93.5**	181.3	(87.8)	Impairment loss from NeuroDerm's projects(84.5), etc.
Current assets	**619.5**	593.5	26.0	
Inventories	**86.5**	80.3	6.2	
Trade and other receivables	**123.2**	108.6	14.6	
Other financial assets	**292.9**	300.3	(7.4)	
Cash and cash equivalents	**104.0**	83.1	21.0	Refer to "(2) Cash Flow Statement"
Liabilities	**185.0**	188.4	(3.4)	
Non-current liabilities	**87.7**	90.3	(2.6)	
Other non-current liabilities	**58.3**	40.9	17.4	
Current liabilities	**97.3**	98.0	(0.7)	
Trade and other payables	**37.1**	32.1	5.0	
Equity	**807.0**	857.9	(50.9)	
Share capital	**50.0**	50.0	-	
Capital surplus	**448.0**	448.0	(0.1)	
Retained earnings	**311.7**	358.4	(46.8)	Net loss for the period 51.0, etc.

(2) Cash Flow Statement

[Billion yen]

	Q2 FY2020	Q2 FY2019	Increase (decrease)
Cash and cash equivalents at beginning of year	**83.1**	111.9	(28.8)
Cash flows from operating activities	**17.6**	19.5	(1.9)
Profit before tax for the period	**(61.6)**	12.1	(73.7)
Depreciation and amortization	**7.6**	7.5	0.1
Impairment loss	**84.5**	0.1	84.5
Loss on sales of Property, Plant and Equipment	**(8.1)**	-	(8.1)
Trade receivable and payable	**(9.7)**	5.1	(14.8)
Other	**4.8**	(5.4)	10.2
Cash flows from investing activities	**6.5**	(21.9)	28.5
Purchase (proceeds from sales) of property, plant and equipment	**3.9**	(4.9)	8.8
Purchase (Proceeds from sales) of investments	**64.7**	(15.9)	80.6
Increase in deposits	**(65.0)**	(0.0)	(65.0)
Other	**3.0**	(1.1)	4.1
Cash flows from financing activities	**(3.0)**	(19.8)	16.8
Effect of exchange rate changes on cash and cash equivalents	**(0.2)**	(1.2)	1.0
Net increase(decrease) in cash and cash equivalents	**21.0**	(23.4)	44.4
Increase by transfer to assets held for sales	**-**	0.1	(0.1)
Cash and cash equivalents at the end of period	**104.0**	88.5	15.5

(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems

[Billion yen]

Occurring basis	Q2 FY2020	Q2 FY2019	Increase (decrease)
Investment in property, plant and equipment	**9.4**	5.8	3.6
Investment in information systems	**0.6**	0.5	0.1

(4) Depreciation and Amortization Costs

[Billion yen]

	Q2 FY2020	Q2 FY2019	Increase (decrease)
Property, plant and equipment	**5.6**	5.6	0.0
Intangible assets	**0.6**	0.6	(0.0)
Intangible assets with products	**1.3**	1.3	0.1

3 Forecasts for FY2020

(Amounts less than ¥ 100 million are rounded)

(1) Revised Consolidated Forecasts of Profit and Loss

[Billion yen]

	Revised on Nov.4	Comparison to original on May 13			FY2019 Actual	Notes [Comparison to original]
		amount	Increase (decrease)	Change %		
Revenue	**373.0**	**383.5**	(10.5)	(2.7)	379.8	Refer to "(2) Sales Revenue Forecasts for Main Products"
Domestic	**312.2**	**314.1**	(1.9)	(0.6)	314.0	
Overseas	**60.8**	**69.4**	(8.6)	(12.4)	65.8	
Overseas sales ratio	**16.3%**	**18.1%**			17.3%	
Cost of sales	**187.5**	**187.5**	-	-	181.0	
Sales cost ratio	**50.3%**	**48.9%**			47.7%	
Gross profit	**185.5**	**196.0**	(10.5)	(5.4)	198.8	
SG&A expenses, etc.	**168.5**	**186.0**	(17.5)	(9.4)	179.7	Shrinkage in sales promotion and delay in R&D expenses incurrence
R&D expenses	**72.5**	**83.5**	(11.0)	(13.2)	79.4	
Core operating profit*1	**17.0**	**10.0**	7.0	70.0	19.1	
Non-recurring items*2	**(79.5)**	**7.0**	(86.5)	-	(25.1)	Impairment loss from NeuroDerm's projects: 84.5
Operating profit*2	**(62.5)**	**17.0**	(79.5)	-	(6.1)	
Profit before tax for the period*2	**(62.0)**	**17.5**	(79.5)	-	(6.5)	
Net profit for the period*2	**(55.0)**	**5.5**	(60.5)	-	(9.4)	
Net profit attributable to owners of the Company*2	**(52.5)**	**8.5**	(61.0)	-	0.1	

Exchange rate

[Yen]

	Revised on Nov.4	Original on May 13	FY2019 average
USD	**108.00**	**108.00**	108.95

(2) Revised Sales Revenue Forecasts for Main Products

[Billion yen]

	Revised on Nov.4	Comparison to original on May 13			FY2019 Actual
		amount	Increase (decrease)	Change %	
Domestic ethical drugs	**302.3**	**303.6**	(1.3)	(0.4)	304.4
Priority products	**183.0**	**182.4**	0.6	0.3	177.1
Remicade	**45.0**	**44.8**	0.2	0.4	53.4
Simponi	**42.7**	**42.3**	0.4	0.9	41.0
Stelara	**31.9**	**32.8**	(0.9)	(2.7)	26.0
Tenelia	**14.9**	**14.9**	-	-	15.2
Canaglu	**9.8**	**9.2**	0.6	6.5	8.8
Canalia	**9.3**	**9.3**	-	-	6.7
Vafseo (launched in Aug.)	**0.5**	**0.2**	0.3	150.0	-
Lexapro	**14.8**	**14.6**	0.2	1.4	15.0
Rupafin	**10.0**	**10.2**	(0.2)	(2.0)	6.8
Imusera	**4.1**	**4.1**	-	-	4.2
Vaccines	**40.8**	**41.0**	(0.2)	(0.5)	39.0
Influenza vaccine	**13.2**	**12.2**	1.0	8.2	12.6
Tetrabik	**11.1**	**11.3**	(0.2)	(1.8)	9.5
Mearubik	**6.4**	**6.4**	-	-	6.0
JEBIK V	**5.3**	**5.3**	-	-	5.2
Varicella vaccine	**4.8**	**4.8**	-	-	4.9
Long-listed drugs, etc.	**78.5**	**80.2**	(1.7)	(2.1)	88.3
Overseas ethical drugs	**47.0**	**50.9**	(3.9)	(7.7)	49.7
Radicava	**20.1**	**22.4**	(2.3)	(10.3)	23.1
Royalty revenue, etc.	**15.2**	**19.9**	(4.7)	(23.6)	17.4
Royalty from INVOKANA	**Undisclosed**	**Undisclosed**	-	-	5.7
Royalty from GILENYA*3	**Undisclosed**	**Undisclosed**	-	-	8.5

*1: As for COVID-19 impact, decreased expenses by shrinkage in sales promotion and delay in R&D expenses incurrence would overtake sales decrease by ¥3.5 billion.

*2: Brackets indicate expense and loss

*3: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

4 Five-Year Financial Data

(Amounts less than ¥100 million are rounded)

(1) Profit and Loss

[Billion yen]

	FY2016	FY2017	FY2018	FY2019	Q2 FY2020	FY2020 forecasts
Revenues	424.0	433.9	424.8	379.8	187.3	373.0
Cost of sales	164.4	169.8	180.6	181.0	94.8	187.5
Gross profit	259.6	264.1	244.1	198.8	92.5	185.5
SG&A expenses, etc.	165.1	185.6	188.3	179.7	77.9	168.5
R&D expenses	64.8	79.1	86.5	79.4	33.9	72.5
Core operating profit	94.5	78.5	55.8	19.1	14.6	17.0
Operating profit	94.1	77.3	50.3	(6.1)	(61.9)	(62.5)
Profit before tax	96.1	78.8	50.4	(6.5)	(61.6)	(62.0)
Net profit for the period	68.9	54.0	32.2	(9.4)	(52.7)	(55.0)
Net profit attributable to owners of the Company	71.3	58.0	37.4	0.1	(51.0)	(52.5)

(2) Balance Sheet

[Billion yen]

	End of FY2016	End of FY2017	End of FY2018	End of FY2019	End of Q2 FY2020
Assets	984.5	1,048.4	1,056.3	1,046.3	992.0
Non-current assets	300.8	462.9	467.9	452.8	372.5
Current assets	683.8	585.5	588.4	593.5	619.5
Liabilities	113.1	153.6	146.0	188.4	185.0
Non-current liabilities	24.7	55.4	54.3	90.3	87.7
Current liabilities	88.4	98.2	91.7	98.0	97.3
Equity	871.4	894.8	910.3	857.9	807.0

(3) Other Financial Data

[Billion yen]

	FY2016	FY2017	FY2018	FY2019	Q2 FY2020	FY2020 forecasts
Cash flows from operating activities	59.8	66.9	41.5	49.4	17.6	-
Cash flows from investing activities	(10.6)	(19.2)	(31.2)	(39.2)	6.5	-
Cash flows from financing activities	(24.4)	(32.5)	(25.9)	(37.9)	(3.0)	-
Investments in property, plant and equipment	14.5	6.2	8.6	15.5	10.0	18.2
Depreciation and Amortization Costs	10.5	11.5	11.5	10.9	7.6	15.7
Property, plant and equipment	7.3	7.6	7.1	7.0	5.6	11.4
Intangible assets including intangible assets with products	3.1	4.0	4.4	4.0	1.9	4.3
Ratio of equity attributable to owners of the Company to total assets [%]	87.4	84.2	85.0	81.4	81.0	-
ROE [%]	8.5	6.6	4.2	0.0	-	-
Basic earnings per share [¥]	127.03	103.35	66.64	0.26	-	-
Equity attributable to owners of the Company per share [¥]	1,533.91	1,574.26	1,600.64	1,519.22	1,431.57	-

(4) Number of Employees

	End of FY2016	End of FY2017	End of FY2018	End of FY2019	End of Q2 FY2020	Forecasts for end of FY2020
Consolidated	7,280	7,187	7,228	6,987	6,910	7,000
Non-consolidated	4,239	4,222	4,111	3,764	3,513	3,450

5 Quarterly Trend

(Amounts less than ¥ 100 million are rounded)

(1) Profit and Loss

[Billion yen]

	FY2019					FY2020		
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full-year Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Full-year Forecasts
Revenue	98.1	90.0	109.3	82.4	379.8	91.8	95.5	373.0
	25.8%	23.7%	28.8%	21.7%	100.0%	24.6%	25.6%	100.0%
Domestic	80.8	73.9	92.6	66.7	314.0	75.7	79.3	312.2
	25.7%	23.5%	29.5%	21.3%	100.0%	24.3%	25.4%	100.0%
Overseas	17.4	16.1	16.7	15.7	65.8	16.1	16.2	60.8
	26.4%	24.5%	25.3%	23.8%	100.0%	26.4%	26.7%	100.0%
Cost of sales	44.8	43.7	54.6	38.0	181.0	45.6	49.2	187.5
Sales cost ratio	45.6%	48.6%	49.9%	46.1%	47.7%	49.7%	51.6%	50.3%
Gross profit	53.3	46.3	54.7	44.5	198.8	46.2	46.3	185.5
	26.8%	23.3%	27.5%	22.4%	100.0%	24.9%	24.9%	100.0%
SG&A expenses, etc.	43.6	44.3	42.3	49.6	179.7	36.6	41.3	168.5
	24.3%	24.7%	23.5%	27.6%	100.0%	21.7%	24.5%	100.0%
R&D expenses	19.9	19.9	17.8	21.9	79.4	15.3	18.6	72.5
	25.1%	25.0%	22.4%	27.6%	100.0%	21.1%	25.7%	100.0%
Core operating profit*	9.8	1.9	12.5	(5.1)	19.1	9.6	5.0	17.0
	51.2%	10.2%	65.5%	(26.9%)	100.0%	56.3%	29.3%	100.0%
Operating profit*	9.6	2.9	12.4	(31.1)	(6.1)	17.7	(79.6)	(62.5)
	-	-	-	-	-	-	-	-
Profit before tax*	9.2	2.9	12.5	(31.1)	(6.5)	17.8	(79.4)	(62.0)
	-	-	-	-	-	-	-	-
Net profit attributable to owners of the Company*	6.9	1.4	9.9	(18.1)	0.1	11.5	(62.4)	(52.5)
	-	-	-	-	-	-	-	-

Note: The progress rates show in the lower of each cell, except for "cost of sales".

*Brackets indicate expense and loss

(2) Sales Revenue of Main Products

[Billion yen]

	FY2019					FY2020		
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full-year actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Full-year Forecasts
Domestic ethical drugs	78.2	71.0	90.5	64.7	304.4	73.3	77.0	302.3
	25.7%	23.3%	29.7%	21.3%	100.0%	24.2%	25.5%	100.0%
Priority products	46.5	42.2	49.1	39.2	177.1	45.3	44.5	183.0
	26.3%	23.8%	27.7%	22.2%	100.0%	24.8%	24.3%	100.0%
Remicade	14.4	13.2	14.9	10.9	53.4	11.9	11.5	45.0
	27.1%	24.7%	27.9%	20.4%	100.0%	26.4%	25.6%	100.0%
Simponi	10.5	9.9	11.2	9.3	41.0	10.7	10.5	42.7
	25.7%	24.3%	27.5%	22.6%	100.0%	25.0%	24.7%	100.0%
Stelara	6.2	6.4	7.8	5.7	26.0	7.0	7.0	31.9
	23.8%	24.6%	29.9%	21.8%	100.0%	21.8%	21.9%	100.0%
Tenelia	4.7	3.4	4.0	3.1	15.2	4.1	3.9	14.9
	30.9%	22.3%	26.3%	20.5%	100.0%	27.6%	25.9%	100.0%
Canaglu	2.2	1.9	2.5	2.3	8.8	2.5	2.5	9.8
	24.4%	22.0%	28.1%	25.5%	100.0%	25.9%	25.5%	100.0%
Canalia	2.2	1.6	1.8	1.2	6.7	2.5	2.5	9.3
	32.7%	23.0%	26.1%	18.2%	100.0%	27.3%	26.6%	100.0%
Vafseo (launched in Aug.)	-	-	-	-	-	-	0.3	0.5
	-	-	-	-	-	-	60.6%	100.0%
Lexapro	3.9	3.6	4.2	3.3	15.0	3.9	3.7	14.8
	26.1%	23.8%	27.9%	22.3%	100.0%	26.2%	25.2%	100.0%
Rupafin	1.3	1.2	1.7	2.6	6.8	1.7	1.6	10.0
	18.5%	18.4%	24.6%	38.5%	100.0%	16.6%	15.6%	100.0%
Imusera	1.1	1.0	1.2	0.9	4.2	1.1	1.0	4.1
	27.0%	24.4%	27.7%	20.9%	100.0%	26.8%	25.3%	100.0%
Vaccines	7.3	8.4	17.2	6.1	39.0	7.5	13.6	40.8
	18.7%	21.6%	44.1%	15.6%	100.0%	18.4%	33.4%	100.0%
Influenza vaccine	(0.0)	1.8	10.6	0.2	12.6	(0.0)	6.4	13.2
	(0.1%)	14.3%	84.3%	1.6%	100.0%	(0.3%)	48.2%	100.0%
Tetrabik	2.4	2.2	2.5	2.4	9.5	2.7	2.5	11.1
	25.0%	23.2%	26.5%	25.3%	100.0%	24.1%	22.3%	100.0%
Mearubik	1.9	1.6	1.3	1.2	6.0	1.9	1.8	6.4
	31.9%	27.1%	21.2%	19.8%	100.0%	29.6%	28.3%	100.0%
JEBIK V	1.5	1.4	1.3	1.0	5.2	1.4	1.5	5.3
	29.3%	26.6%	25.1%	19.0%	100.0%	27.3%	27.8%	100.0%
Varicella vaccine	1.3	1.2	1.3	1.1	4.9	1.3	1.2	4.8
	26.2%	24.7%	26.1%	23.1%	100.0%	26.3%	25.6%	100.0%
Long-listed drugs, etc.	24.3	20.4	24.2	19.4	88.3	20.4	18.9	78.5
	27.6%	23.1%	27.4%	22.0%	100.0%	26.0%	24.1%	100.0%
Overseas ethical drugs	12.6	12.3	12.6	12.2	49.7	12.6	12.5	47.0
	25.3%	24.7%	25.4%	24.6%	100.0%	26.9%	26.6%	100.0%
Radicava	6.1	5.5	5.7	5.8	23.1	5.6	5.5	20.1
	26.5%	23.8%	24.8%	24.9%	100.0%	27.8%	27.4%	100.0%
Royalty revenue, etc.	5.1	4.2	4.4	3.8	17.4	3.8	4.1	15.2
	29.0%	23.9%	25.2%	21.9%	100.0%	24.7%	26.8%	100.0%
Royalty from INVOKANA	2.1	2.0	2.4	2.0	8.5	2.0	2.5	Undisclosed
	24.2%	23.9%	28.3%	23.7%	100.0%	-	-	-
Royalty from GILENYA*1	1.7	1.6	1.4	1.1	5.7	1.1	0.9	Undisclosed
	29.3%	27.7%	23.8%	19.2%	100.0%	-	-	-

Note: The each figure in the lower displays the progress rate.

*1 MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

6 State of New Product Development (as of Oct. 25, 2020)

i. Immuno-inflammation

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/licensee
MT-5547 (Fasinumab)	Fully human anti-NGF monoclonal antibody (Osteoarthritis)	Japan Phase 2/3	Licensed from Regeneron (US)
MT-7117 (Dersimelagon)	Selective melanocortin 1 receptor agonist (Erythropoietic protoporphyria, X-Linked protoporphyria)	Global Phase 3	In-house
MT-1303 (Amiselimod)	S1P receptor functional antagonist (Multiple sclerosis)	Europe Phase 2	In-house
	(Crohn's disease)	Japan Phase 2	
MT-2990	Fully human anti-interleukin-33 (IL-33) monoclonal antibody (Endometriosis)	Global Phase 2	In-house

ii. Diabetes and kidney

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/licensee
TA-7284 Canaglu/INVOKANA (Canagliflozin)	SGLT2 inhibitor (Diabetic nephropathy)	Asia Filed	In-house
		Japan Phase 3	
MP-513 Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Asia Filed	In-house
		China Filed (Sep. 2019)	
		Europe Phase 2	
MT-3995 (Apararenone)	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Europe Phase 2	In-house
		Japan Phase 2	
	(Non-alcoholic steatohepatitis: NASH)	Japan Phase 2	

※ Asia: excluding Japan and China

iii. Central nervous system

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/licensee
MCI-186 Radicut/Radicava (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS)	Asia Filed	In-house
MP-214 (Cariprazine)	Dopamine D3/D2 receptor partial agonist (Schizophrenia)	Asia Filed	Licensed from Gedeon Richter (Hungary)
MT-0551 (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (Neuromyelitis optica spectrum disorder: NMOSD)	Japan Filed (June 2020) Asia Filed	Licensed from Viela Bio (US)
MT-210 (Roluperidone)	5-HT2A/Sigma 2 receptor antagonist (Schizophrenia)	US, Europe Phase 3	Licensed to Minerva Neurosciences (US)
MT-5199 (Valbenazine)	Vesicular monoamine transporter type 2 inhibitor (Tardive dyskinesia)	Japan Phase 2/3 Asia Filed	Licensed from Neurocrine Biosciences (US)
ND0612 (Levodopa/Carbidopa)	Continuous SC pump (Parkinson's disease)	Global Phase 3	In-house
MT-1186 (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS / Oral suspension)	Global Phase 3	In-house
MT-8554 (Elismetrep)	TRPM8 antagonist (Painful diabetic peripheral neuropathy)	Europe Phase 2	In-house
	(Vasomotor symptoms associated with menopause)	Global Phase 2	
MT-3921	Anti-RGMa antibody (Spinal cord injury)	Phase 1	Co-developed with Osaka University (Japan)

iv. Vaccines

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/licensee
MT-2355	Combined vaccine (Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants)	Japan Phase 3	Co-developed with The Research Foundation for Microbial Diseases of Osaka University (Japan)
MT-2271	Plant-based VLP vaccine (Prophylaxis of seasonal influenza/adults)	Canada Filed (Sep. 2019) Europe Phase 3	Medicago product (Canada)
	(Prophylaxis of seasonal influenza/elderly)	Europe Phase 3	
MT-8972	Plant-based VLP vaccine (Prophylaxis of H5N1 influenza)	Canada Phase 2	Medicago product (Canada)
MT-7529	Plant-based VLP vaccine (Prophylaxis of H7N9 influenza)	Phase 1	Medicago product (Canada)
MT-5625	Plant-based VLP vaccine (Prophylaxis of rotavirus gastroenteritis)	Phase 1	Medicago product (Canada)
MT-2766	Plant-based VLP vaccine (Prophylaxis of COVID-19)	Phase 1	Medicago product (Canada)

※ Asia: excluding Japan and China

v. Others

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/licensee
MT-4580 Orkedia (Evocalcet)	Ca sensing receptor agonist (Secondary Hyperparathyroidism)	China, Asia Phase 3	Licensed to Kyowa Kirin (Japan)
MT-4129	Cardiovascular system, etc.	Phase 1	In-house
MT-8633/TR1801-ADC	Anti-c-Met ADC* (Solid tumor)	Phase 1	In-house Collaborate with Open Innovation Partners (Japan)

*Antibody drug conjugate

Changes Since Previous Announcement

Development code Product name (Generic name)	Category (Indications)	Previous Announcement	As of Oct 25, 2020	Origin / licensee
MP-214 (Cariprazine)	Dopamine D3/D2 receptor partial agonist (Schizophrenia)	Asia Filed	Malaysia Approved (Aug. 2020)	Licensed from Gedeon Richter (Hungary)
TA-7284 Canaglu/INVOKANA (Canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	Asia Filed	Indonesia Approved (Sep. 2020)	In-house
MT-0551 (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (Neuromyelitis optica spectrum disorder: NMOSD)	Asia Phase 3	Asia Filed	Licensed from Viela Bio (US)
TAU-284 Talion (Bepotastine)	Selective histamine H1 receptor antagonist, anti-allergic agent (Allergic rhinitis, Urticaria)	Asia Filed	Deleted (Withdrawal of application)	Licensed from Ube Industries (Japan)
MT-2990	Fully human anti-interleukin-33 (IL-33) monoclonal antibody (Seasonal Allergic Rhinitis)	Phase 1	Deleted (Discontinued)	In-house

※ Asia: excluding Japan and China